Scholarlink

<p><i>Artemisia absinthium</i>, a member of the Asteraceae family, is a widely recognized medicinal herb traditionally used to treat gastric pain, stimulate cardiac function, and alleviate hepatic complications. De novo transcriptome sequencing of fresh <i>Artemisia absinthium</i> leaf tissue was conducted using the Illumina NextSeq500 platform. BLAST analysis against the NCBI non-redundant (nr) protein database showed that 28.5% (12,710) of the transcripts matched known sequences, while 71.5% (31,859) were non-homologous. About 22% (9,774) showed homology with both nr and SwissProt databases, indicating high-confidence functional annotations. Functional analysis revealed <i>Artemisia absinthium</i> transcripts are mainly involved in terpenoid and flavonoid biosynthesis. Comparative analysis with other Artemisia species highlighted <i>A. absinthium</i>-specific GO terms and unique secondary metabolites. Furthermore, the transcriptome analysis revealed the biosynthetic potential of <i>Artemisia absinthium</i> to produce the metabolites genistein and apigenin. Downstream analyses predicted that both genistein and apigenin possess drug-like ADME properties and exhibit inhibitory potential against SARS-CoV-2 target. These findings suggest that the antiviral activity previously reported for <i>Artemisia absinthium</i> may be attributed to its biosynthetic capacity to produce genistein and apigenin. This information may prove valuable for guiding metabolic engineering strategies aimed at the commercial production of these metabolites from <i>A. absinthium</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

De novo transcriptome sequencing of Artemisia absinthium predicted anti-SARS-CoV2 (COVID-19) bioactive secondary metabolites

  • 期刊论文

  • 发表日期：

    2026年1月28日

查看全文
  • Umar Khitab Khan,
  • Awais Ali,
  • Syed Luqman Ali,
  • Shahid Aziz,
  • Asifullah Khan,
  • Nusrat Shafiq,
  • Bushra Shakoor,
  • Matheus Finger Ramos de Oliveira

摘要

Artemisia absinthium, a member of the Asteraceae family, is a widely recognized medicinal herb traditionally used to treat gastric pain, stimulate cardiac function, and alleviate hepatic complications. De novo transcriptome sequencing of fresh Artemisia absinthium leaf tissue was conducted using the Illumina NextSeq500 platform. BLAST analysis against the NCBI non-redundant (nr) protein database showed that 28.5% (12,710) of the transcripts matched known sequences, while 71.5% (31,859) were non-homologous. About 22% (9,774) showed homology with both nr and SwissProt databases, indicating high-confidence functional annotations. Functional analysis revealed Artemisia absinthium transcripts are mainly involved in terpenoid and flavonoid biosynthesis. Comparative analysis with other Artemisia species highlighted A. absinthium-specific GO terms and unique secondary metabolites. Furthermore, the transcriptome analysis revealed the biosynthetic potential of Artemisia absinthium to produce the metabolites genistein and apigenin. Downstream analyses predicted that both genistein and apigenin possess drug-like ADME properties and exhibit inhibitory potential against SARS-CoV-2 target. These findings suggest that the antiviral activity previously reported for Artemisia absinthium may be attributed to its biosynthetic capacity to produce genistein and apigenin. This information may prove valuable for guiding metabolic engineering strategies aimed at the commercial production of these metabolites from A. absinthium.